<DOC>
	<DOCNO>NCT01336088</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability ADX48621 Parkinson 's disease patient follow four week dose . The secondary objective study include evaluation efficacy ADX48621 compare placebo reduce levodopa induce dyskinesia patient Parkinson 's ; evaluation effect ADX48621 symptoms Parkinson 's disease patient ability function , evaluation effect coadministration ADX48621 L-dopa efficacy .</brief_summary>
	<brief_title>ADX48621 Treatment Levodopa Induced Dyskinesia Patients With Parkinson 's Disease</brief_title>
	<detailed_description>First study ADX48621 male female Parkinson 's disease patient levodopa-induced dyskinesia . Four week , double-blind , placebo-controlled dose titration 50 mg daily 100 mg three time daily , start week 4 . Safety tolerability assess adverse event enquiry , heart rate blood pressure , 12-lead ECG , haematology biochemistry . Efficacy assessment include Abnormal Involuntary Movement Scale ( AIMS ) , Unified Parkinson 's Disease rating Scale ( UPDRS ) patient PD symptom diary , Hospital Anxiety Depression Scale ( HADS ) , patient clinician global impression change PD dyskinesia ( PGIC CGIC ) .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>outpatient idiopathic PD accord UK Parkinson 's Disease Society Brain Bank Clinical Diagnosis Criteria ( UKPDSBBCDC ) experience moderately disabling dyskinesia ( screen visit UPDRS 33 score≥2 ) mAIMS score baseline ≥ 7 score ≥ 3 least one body area surgical treatment Parkinson 's disease ( e.g . Deep Brain Stimulation , within last year plan study ) unstable coexist psychiatric disease include cognitive impairment , accord Investigator , could interfere conduct study history significant medical condition may affect safety patient preclude adequate participation study . pregnant breastfeeding . Female patient childbearing potential must use adequate contraceptive method ( e.g . oral contraceptive , doublebarrier method , intrauterine device , intramuscular hormonal contraceptive ) , negative pregnancy test Screening Other protocoldefined inclusion exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>dyskinesia</keyword>
	<keyword>Parkinson 's disease</keyword>
</DOC>